SRX246
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V 1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders. It is an azetidinone derivative, and was developed from LY-307174 as a lead compound. A Phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder showed a reduction in aggression not any higher than that of the placebo. In another Phase II trial it decreased aggression in patients with Huntington's disease, especially those in the middle and late stages who had a history of violent behavior. It was also being studied for the treatment of post-traumatic stress disorder, but the study was terminated due to lack of funding.
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V 1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders. It is an azetidinone derivative, and was developed from LY-307174 as a lead compound. A Phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder showed a reduction in aggression not any higher than that of the placebo. In another Phase II trial it decreased aggression in patients with Huntington's disease, especially those in the middle and late stages who had a history of violent behavior. It was also being studied for the treatment of post-traumatic stress disorder, but the study was terminated due to lack of funding.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372357011 under CC BY-SA 4.0; modifications have been made.